keyword
MENU ▼
Read by QxMD icon Read
search

Psychosis in parkinson

keyword
https://www.readbyqxmd.com/read/28089250/pathology-of-behavior-in-pd-what-is-known-and-what-is-not
#1
REVIEW
Kaylena A Ehgoetz Martens, Simon J G Lewis
Abnormal behavior in Parkinson's disease (PD) stems from a complex orchestration of impaired neural networks that result from PD-related neurodegeneration across multiple levels. Typically, cellular and tissue abnormalities generate neurochemical changes and disrupt specific regions of the brain, in turn creating impaired neural circuits and dysfunctional global networks. The objective of this chapter is to provide an overview of the array of pathological changes that have been linked to different behavioral symptoms of PD such as depression, anxiety, apathy, fatigue, impulse control disorders, psychosis, sleep disorders and dementia...
December 29, 2016: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/28057432/pattern-of-cognitive-impairment-in-patients-with-parkinson-s-disease-and-psychosis-a-critical-review
#2
REVIEW
Abhishek Lenka, Shantala Hegde, Shyam Sundar Arumugham, Pramod Kumar Pal
Psychosis is one of the debilitating non-motor symptoms (NMS) of Parkinson's disease (PD). Cognitive impairment is considered to be a risk factor for emergence of psychosis in PD. Early detection of relevant cognitive impairment may serve as a predictor for development of psychosis, with implications for prevention and early intervention. However, the exact pattern of cognitive impairment associated with psychosis is not clear. In this article, we aim to critically review the literature on case-control studies in PD patients with and without psychosis in order to understand the pattern of cognitive impairment in those with psychosis...
December 29, 2016: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/28027109/the-relationship-between-early-haloperidol-response-and-associated-extrapyramidal-side-effects
#3
Sean A Rasmussen, Patricia I Rosebush, Michael F Mazurek
BACKGROUND: Early response to antipsychotic medication within 2 weeks of initiating treatment can predict psychiatric outcomes. However, it is unclear whether early response is also predictive of extrapyramidal side effects (EPSs) associated with antipsychotic medications. METHODS: In this study, we investigated 136 consecutive antipsychotic-naive, first-episode psychosis patients naturalistically treated with haloperidol. Patients were assessed at baseline and weekly after treatment initiation using the Brief Psychiatric Rating Scale, Hamilton Depression Rating Scale, and Hamilton Anxiety Rating Scale...
February 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27955830/inverse-agonists-what-do-they-mean-for-psychiatry
#4
David Nutt, Stephen Stahl, Pierre Blier, Filippo Drago, Joseph Zohar, Sue Wilson
The nomenclature of drugs is a critical aspect of science, since it can direct research and optimize treatment choices. Traditionally drugs acting on CNS receptors have been classified as either agonists or antagonists. Recently a new class of ligand, the inverse agonist, has been identified in some receptor systems. Inverse agonists have opposite actions to those of agonists but the effects of both of these can be blocked by antagonists. Pimavanserin is a new 5-HT2A receptor acting drug that has been given market authorization for psychosis in Parkinson׳s disease...
December 7, 2016: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27943472/hospital-care-for-mental-health-and-substance-abuse-conditions-in-parkinson-s-disease
#5
Allison W Willis, Dylan P Thibault, Peter N Schmidt, E Ray Dorsey, Daniel Weintraub
OBJECTIVE: The objective of this study was to examine mental health conditions among hospitalized individuals with Parkinson's disease in the United States. METHODS: This was a serial cross-sectional study of hospitalizations of individuals aged ≥60 identified in the Nationwide Inpatient Sample dataset from 2000 to 2010. We identified all hospitalizations with a diagnosis of PD, alcohol abuse, anxiety, bipolar disorder, depression, impulse control disorders, mania, psychosis, substance abuse, and attempted suicide/suicidal ideation...
December 2016: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/27830568/psychosis-in-parkinson-disease-a-review-of-etiology-phenomenology-and-management
#6
REVIEW
Niyatee Samudra, Neepa Patel, Kyle B Womack, Pravin Khemani, Shilpa Chitnis
Parkinson disease psychosis (PDP) is a common phenomenon in Parkinson disease (PD) patients treated with dopaminergic drugs, and is associated with high morbidity and mortality. It also correlates with depression and dementia, and can contribute to considerable caregiver stress and burnout. While symptoms can be relieved by decreasing doses or number of anti-PD medications, this may lead to an unacceptable worsening of motor function. When general medical or psychiatric conditions have been ruled out, and decreasing dopaminergic agents is not effective in treating psychosis, therapies include atypical antipsychotics, primarily clozapine and quetiapine...
December 2016: Drugs & Aging
https://www.readbyqxmd.com/read/27800022/evidence-for-the-use-of-pimavanserin-in-the-treatment-of-parkinson-s-disease-psychosis
#7
REVIEW
Harini Sarva, Claire Henchcliffe
Parkinson's disease (PD) is a progressive neurodegenerative disorder with both motor and nonmotor symptoms (NMS), leading to significant morbidity and caregiver burden. Psychosis is common but is under recognized by physicians. When present, it increases the patient's risk of hospitalization and nursing home placement and caregiver burden. Although the atypical antipsychotic agent, clozapine, has been considered the gold standard treatment, severe agranulocytosis in 0.38% of patients and more commonly milder leukopenia, resulting in frequent blood testing, limit its use...
November 2016: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/27789118/adverse-structural-and-functional-effects-of-marijuana-on-the-brain-evidence-reviewed
#8
REVIEW
David E Mandelbaum, Suzanne M de la Monte
The growing use and legalization of cannabis are leading to increased exposures across all age groups, including in adolescence. The touting of its medicinal values stems from anecdotal reports related to treatment of a broad range of illnesses including epilepsy, multiple sclerosis, muscle spasms, arthritis, obesity, cancer, Alzheimer disease, Parkinson disease, post-traumatic stress, inflammatory bowel disease, and anxiety. However, anecdotal data and the high level of interest in this treatment must not obscure objective assessments of any potential and realized short- and long-term adverse effects of cannabis, particularly with respect to age of onset and chronicity of exposure...
January 2017: Pediatric Neurology
https://www.readbyqxmd.com/read/27785919/pharmacotherapies-for-parkinson-s-disease-symptoms-related-to-cholinergic-degeneration
#9
Santiago Perez-Lloret, María Cecilia Peralta, Francisco J Barrantes
Dopamine depletion is one of the most important features of Parkinson's Disease (PD). However, insufficient response to dopaminergic replacement therapy suggests the involvement of other neurotransmitter systems in the pathophysiology of PD. Cholinergic degeneration contributes to gait impairments, cognitive impairment, psychosis, and REM-sleep disturbances, among other symptoms. Areas covered: In this review, we explore the idea that enhancing cholinergic tone by pharmacological or neurosurgical procedures could be a first-line therapeutic strategy for the treatment of symptoms derived from cholinergic degeneration in PD...
November 7, 2016: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/27742525/validation-of-the-national-institute-of-neurological-disorders-and-stroke-criteria-for-psychosis-in-parkinson-disease
#10
Pedro Caldana Gordon, Maria Sheila G Rocha, Roberta Gomes Kauark, Carlos Daniel Miranda Costa, Maira Okada de Oliveira, Fabio Godinho, Vanderci Borges
OBJECTIVES: Parkinson disease (PD) psychosis is a condition associated with several negative outcomes. Despite its impact, there is a lack of validated diagnostic tools for this condition. In this study, we aim to verify the validity of the proposed NINDS criteria for PD psychosis and explore its possible applications in clinical practice. DESIGN, SETTINGS, PARTICIPANTS: We prospectively selected 104 subjects with idiopathic PD referred to a movement disorder clinic for a cross-sectional evaluation...
January 2017: American Journal of Geriatric Psychiatry
https://www.readbyqxmd.com/read/27721206/the-cortical-thickness-correlates-of-clinical-manifestations-in-the-mid-stage-sporadic-parkinson-s-disease
#11
Xia Deng, Chun-Yan Tang, Jie Zhang, Lei Zhu, Zun-Chun Xie, Hong-Han Gong, Xiang-Zuo Xiao, Ren-Shi Xu
The cortical thickness has gained an extensive attention as a pathological alteration of sporadic Parkinson's disease (sPD), the alteration of pathological cortical thickness may distinctly contribute to the consistent clinical manifestations. Therefore, we investigated the cortical thickness correlates of clinical manifestations in the mid-stage sPD from the Han population of Chinese mainland (HPCM). A sample of 67 mid-stage sPD patients and 35 matched controls from HPCM were performed a corticometry of magnetic resonance imaging (MRI) and the assessment of clinical manifestations including the demographic and disease-related characteristics, and underwent the final analysis of the cortical thickness correlates with the clinical manifestations...
October 28, 2016: Neuroscience Letters
https://www.readbyqxmd.com/read/27719624/treatment-possibilities-for-psychosis-in-parkinson-s-disease-with-an-emphasis-on-the-newly-approved-drug-pimavanserin
#12
Zsófia Majláth, Izabella Obál, László Vécsei
Parkinson's disease (PD) is a progressive neurodegenerative disorder with prominent motor and non-motor symptoms. Psychosis develops in over 40% of PD patients and it is one of the most distressing symptoms for patients and caregivers alike. Until recently, atypical antipsychotics, clozapine and quetiapine were used to treat psychotic symptoms, but treatment was associated with substantial concerns for side-effects of clozapine and unfounded efficacy for quetiapine. Extensive research has shown that the antipsychotic effect of these drugs could be attributed to serotonin 2a receptor (5 HT2a) triggered mechanisms...
October 6, 2016: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/27718013/a-single-dose-of-l-dopa-changes-perceptual-experiences-and-decreases-latent-inhibition-in-parkinson-s-disease
#13
Orsolya Györfi, Helga Nagy, Magdolna Bokor, Oguz Kelemen, Szabolcs Kéri
Despite the well-known neuropsychiatric side effects of dopaminergic medications, the possible subjective psychotomimetic effects of a single dose of L-DOPA in newly diagnosed, drug-naïve patients with Parkinson's disease (PD) are not known. To investigate this question, we used a visual search task for latent inhibition (LI), the Community Assessment of Psychic Experiences (CAPE) scale, and visual analog scales for psychotomimetic effects (perception, relaxation, and dysphoria) in 28 de novo PD patients before (off) and after (on) the adminstration of L-DOPA and in 25 matched healthy control individuals...
October 7, 2016: Journal of Neural Transmission
https://www.readbyqxmd.com/read/27689715/affective-disorders-psychosis-and-dementia-in-a-community-sample-of-older-men-with-and-without-parkinson-s-disease
#14
Osvaldo P Almeida, Kieran McCaul, Graeme J Hankey, Bu B Yeap, Jonathan Golledge, Leon Flicker
BACKGROUND: Dementia and affective and psychotic symptoms are commonly associated with Parkinson's disease, but information about their prevalence and incidence in community representative samples remains sparse. METHODS: We recruited a community-representative sample 38173 older men aged 65-85 years in 1996 and used data linkage to ascertain the presence of PD, affective disorders, psychotic disorders and dementia. Diagnoses followed the International Classification of Disease coding system...
2016: PloS One
https://www.readbyqxmd.com/read/27689617/clinical-complexity-and-use-of%C3%A2-antipsychotics-and-restraints-in%C3%A2-long-term-care-residents-with%C3%A2-parkinson-s-disease
#15
George A Heckman, Alexander M Crizzle, Jonathen Chen, Tamara Pringsheim, Nathalie Jette, Marie-Jeanne Kergoat, Leslie Eckel, John P Hirdes
BACKGROUND: Patients with Parkinson's disease (PD) and/or Parkinsonism are affected by a complex burden of comorbidity. Many ultimately require institutional care, where they may be subject to the application of physical restraints or the prescription of antipsychotic medications, making them more vulnerable to adverse outcomes. OBJECTIVES: The objectives of this paper are to: 1) describe the clinical complexity of older institutionalized persons with PD; and 2) examine patterns and predictors of restraint use and prescription of antipsychotics in this population...
September 29, 2016: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/27686027/parkinson-s-disease-psychosis-as-a-serotonin-dopamine-imbalance-syndrome
#16
Stephen M Stahl
Parkinson's disease psychosis (PDP) is theoretically a serotonin-dopamine imbalance syndrome due to disruption of the normal balance between the serotonergic and dopaminergic neurotransmitter systems in key brain circuits.
October 2016: CNS Spectrums
https://www.readbyqxmd.com/read/27664144/self-reported-symptoms-of-parkinson-s-disease-by-sex-and-disease-duration
#17
Ju Young Shin, Ryan T Pohlig, Barbara Habermann
Parkinson's disease (PD) is a neurodegenerative disease with a wide range of symptom presentations. The purpose of this research was to compare self-reported motor and non-motor symptoms of PD by sex and disease duration. This study was a cross-sectional descriptive survey in community-dwelling people with PD. A total of 141 participants (64.6% response rate; 59.6% men; Mage = 69.7 years) were included. Males reported more rigidity, speech problems, sexual dysfunction, memory problems, and socializing problems than females...
September 23, 2016: Western Journal of Nursing Research
https://www.readbyqxmd.com/read/27658514/-non-criteria-neurologic-manifestations-of-antiphospholipid-syndrome-a-hidden-kingdom-to-be-discovered
#18
Md Asiful Islam, Fahmida Alam, Mohammad Amjad Kamal, Kah Keng Wong, Teguh Haryo Sasongko, Siew Hua Gan
Neurological manifestations or disorders associated with central nervous system (CNS) are one of the most common as well as important clinical characteristics of antiphospholipid syndrome (APS). Although in the last updated (2006) classification criteria of APS its neurological manifestations encompassed only transient ischemic attack (TIA) and stroke, diverse 'non-criteria' neurological disorders or manifestations (headache, migraine, bipolar disorder, transverse myelitis, dementia, chorea, epileptic seizures, multiple sclerosis, psychosis, cognitive impairment, Tourette's syndrome, parkinsonism, dystonia, transient global amnesia, obsessive compulsive disorder and leukoencephalopathy) have been observed in APS patients...
September 20, 2016: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/27629356/current-understanding-of-psychosis-in-parkinson-s-disease
#19
REVIEW
Oluwadamilola O Ojo, Hubert H Fernandez
Psychosis in Parkinson's disease (PD) is one of the greatest determinants of nursing home placement and caregiver stress. Traditionally associated with medications with dopaminergic effect, it has now been linked to other medications and other stressors e.g. systemic illnesses. The development of hallucinations in a PD patient can herald the onset of dementia and usually predicts increased mortality risk. Medication reduction in PD psychosis usually reduces the symptoms; however, this comes at the cost of worsening motor function...
October 2016: Current Psychiatry Reports
https://www.readbyqxmd.com/read/27609312/pimavanserin-for-the-treatment-of-parkinson-s-disease-psychosis
#20
Ines Chendo, Joaquim J Ferreira
INTRODUCTION: Parkinson´s disease (PD) is a synucleinopathy that affects millions of people worldwide and leads to progressive disability. Psychosis is highly prevalent in PD patients and is associated with poor prognosis. Until April 2016, there were no licensed drugs available in the United States of America (USA) for the treatment of PD psychosis (PDP). Pimavanserin is the first Food and Drug Administration approved medicine for the treatment of hallucinations and delusions associated with PDP...
October 2016: Expert Opinion on Pharmacotherapy
keyword
keyword
69147
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"